Compare AMETEK, Inc. (AME) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AMETEK, Inc. vs Mesoblast Limited — how do they compare? AMETEK, Inc. trades at $255.78 (market cap $58.76B), while Mesoblast Limited trades at $16.68 (market cap $2.21B). The key difference: AMETEK, Inc. is far larger — about 26.6× Mesoblast Limited's market cap, and AMETEK, Inc. pays a 0.53% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| AME | MESO | |
|---|---|---|
Market Cap | $58.76B | $2.21B |
Sector | Industrials | Technology |
52-Week High | $256.30 | $20.96 |
52-Week Low | $179.28 | $12.88 |
Enterprise Value | $60.30B | $2.21B |
Dividend Yield | 0.53% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AMETEK, Inc.
Ametek is a diversified industrial conglomerate with over $6 billion in sales. The firm operates through an electronic instruments group and an electromechanical group. EIG designs and manufactures differentiated and advanced instruments for the process, aerospace, power, and industrial end markets. EMG is a focused, niche supplier of highly engineered automation solutions, thermal management systems, specialty metals, and electrical interconnects, among other products. About half of the firm's sales are made in the United States. The firm's asset-light strategy in place for nearly two decades emphasizes growth through acquisitions, new product development through research and development, driving operational efficiencies, and global and market expansion.
Read more on AME →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
